Aptamer therapeutics advance

被引：284

作者：

Lee, Jennifer F. ^{[1
]}

Stovall, Gwendolyn M. ^{[1
]}

Ellington, Andrew D. ^{[1
]}

机构：

[1] Univ Texas, Austin, TX 78712 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2006年 / 10卷 / 03期

关键词：

D O I：

10.1016/j.cbpa.2006.03.015

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Aptamers are selected nucleic acid binding species with affinities and specificities for protein targets that rival those of monoclonal antibodies. Furthermore, aptamers have definite advantages over antibodies, in that they can be chemically synthesized and modifications can be introduced that improve their stabilities and pharmacokinetic properties. A number of aptamers against therapeutically important targets have shown efficacy in cell and animal models, and a handful of aptamers are now in clinical trials or are being used as drugs. Recent advances in selection technologies and a more thorough exploration of how to deliver nucleic acids to target cells and tissues should further speed the process of drug development.

引用

页码：282 / 289

页数：8

共 74 条

[21] HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors [J].